Health · Pharma & Biotech · 3 hrs ago
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Mirum Pharmaceuticals reported a late-stage trial result for Livmarli in ultra-rare liver diseases.
Livmarli is an ileal bile acid transporter inhibitor.
The trial found that it significantly reduced cholestatic pruritus.
The available information does not say what treatment or group Livmarli was compared with.
The result concerns cholestatic pruritus, a symptom named in the trial summary.
No further details about the trial or the company’s next steps are provided.
Mirum Pharmaceuticals reported a late-stage trial success for Livmarli in rare liver diseases.
The company said Livmarli significantly reduced cholestatic pruritus compared with a comparator.
Livmarli is an ileal bile acid transporter inhibitor.
The article did not provide further trial details in the available text.
- Who
- Mirum Pharmaceuticals.
- What
- The company reported a late-stage trial success for Livmarli, which significantly reduced cholestatic pruritus compared with a comparator.
- When
- October 12, 2026, the article’s publication date.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Mirum Pharmaceuticals
- Drug
- Livmarli
- Drug class
- Ileal bile acid transporter inhibitor
- Reported outcome
- Significantly reduced cholestatic pruritus compared with a comparator
Sources
Related news
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
EU approves evolocumab for adults at high cardiovascular risk
Brazil suspends Peptistrong supplement and orders all batches recalled
